IL6 and congenital rubella syndrome: In CAR-T-cell therapy, anti-IL-6 drug therapy is recommended to treat hypotension and hypoxia for patients with a higher grade of CRS.32 When patients are refractory to anti-IL-6 therapy, the usage of corticosteroids182,183 can be considered to inhibit T cell activation by downregulating signal transduction through the IL-2 receptor.